- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00881413
Esomeprazole Versus Pantoprazole to Prevent Peptic Ulcer Rebleeding
April 7, 2015 updated by: Lotung Poh-Ai Hospital
Clinical Effectiveness of Intravenous Esomeprazole Versus Pantoprazole in Preventing Peptic Ulcer Recurrent Bleeding: a Double-Blind Randomized Trial
The aim of this study is to compare the clinical effectiveness of intravenous esomeprazole and pantoprazole in preventing recurrent bleeding in the patients with high-risk bleeding peptic ulcers after successful standard endoscopic hemostasis.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
Endoscopic hemostasis and proton pump inhibitor (PPI) constitute the cornerstone in the management of peptic ulcer bleeding (PUB), which remains a prevalent disorder associated with substantial morbidity and mortality.
Clinical effectiveness of PPI in the management of patients with PUB has been established by compelling evidence derived from a number of randomized trials.
However, whether different PPIs are equally effective has not been investigated.
Esomeprazole, the S-isomer of omeprazole, may achieve faster, more profound and steady acid suppression than other PPIs, but it remains undetermined whether the superiority of pharmacologic efficacy may be translated into advantages in clinical outcomes.
Study Type
Interventional
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- aged more than 18 years
- undergo emergent endoscopy within 24 hours of presentation
- have peptic ulcers in the gastroesophageal junction, stomach, or duodenum
- high-risk stigmata of peptic ulcers: Forrest classification IA~IIB
- endoscopic hemostasis by thermocoagulation or clip placement
Exclusion Criteria:
- pregnant or lactating
- written informed consent not obtained
- initial endoscopic hemostasis fail
- bleeding tendency (platelet count < 50×109/L, prolonged prothrombin time for more than 3 seconds, or were taking anticoagulants)
- PPI use within 14 days of enrollment
- comorbid with severe hepatic or renal insufficiency (serum total bilirubin more than 5 mg/dL, serum creatinine more than 5 mg/dL, or under dialysis)
- bleeding gastric cancers
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Esomeprazole
High-dose esomeprazole
|
Intravenous esomeprazole (Nexium®, AstraZeneca, Sodertalje, Sweden) is administered with 80mg bolus and 8mg/hr infusion for 72 hours.
After 3 days, patients receive oral esomeprazole 40 mg (Nexium®, AstraZeneca, Sodertalje, Sweden) for 2 months
Other Names:
|
Active Comparator: Pantoprazole
High-dose pantoprazole
|
After successful endoscopy, intravenous pantoprazole (Pantoloc®, Nycomed GMBH, Konstanz, Germany) is administered with 80mg bolus and 8mg/hr infusion for 72 hours.
After 3 days, patients receive oral pantoprazole 40 mg (Pantoloc®, Nycomed GMBH, Oranienburg, Germany) for 2 months
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
recurrent bleeding within 14 days of enrollment
Time Frame: 14 days after enrollment
|
14 days after enrollment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Volume of blood transfusion
Time Frame: 14 days after enrollment
|
14 days after enrollment
|
Need for surgery
Time Frame: 14 days after enrollment
|
14 days after enrollment
|
all-cause mortality
Time Frame: 14 days after enrollment
|
14 days after enrollment
|
bleeding-related mortality
Time Frame: 14 days after enrollment
|
14 days after enrollment
|
length of hospital stay
Time Frame: probably one month after enrollment
|
probably one month after enrollment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Hwai-jeng Lin, M.D., Lotung Poh-Ai Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
April 13, 2009
First Submitted That Met QC Criteria
April 13, 2009
First Posted (Estimate)
April 15, 2009
Study Record Updates
Last Update Posted (Estimate)
April 8, 2015
Last Update Submitted That Met QC Criteria
April 7, 2015
Last Verified
April 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Gastrointestinal Diseases
- Stomach Diseases
- Intestinal Diseases
- Duodenal Diseases
- Ulcer
- Peptic Ulcer
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Gastrointestinal Agents
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Esomeprazole
- Pantoprazole
Other Study ID Numbers
- OMCP98004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peptic Ulcer
-
Uayporn KaosombatwattanaCompleted
-
Kaohsiung Veterans General Hospital.Completed
-
AstraZenecaCompleted
-
Chinese University of Hong KongNational Taiwan University Hospital; Okayama University; Tokyo University; Tsuyama... and other collaboratorsCompletedBleeding Peptic UlcerChina
-
South Valley UniversityCompleted
-
Erasme University HospitalGastrostartCompletedPerforated Peptic UlcerNetherlands
-
Azienda USL ModenaRecruiting
-
Assiut UniversityNot yet recruitingPerforated Peptic Ulcer
-
Kyunghee University Medical CenterCompletedActive Peptic Ulcer Disease/GI BleedingKorea, Republic of
Clinical Trials on Esomeprazole
-
TakedaCompletedHealthy ParticipantsUnited States
-
National Taiwan University HospitalMinistry of Science and Technology, Taipei, TaiwanCompleted
-
AstraZenecaCompletedRefractory Reflux EsophagitisJapan
-
Chinese University of Hong KongCompletedBleeding | Peptic UlcerChina
-
Bio-innova Co., LtdNot yet recruiting
-
Onconic Therapeutics Inc.Completed
-
Bio-innova Co., LtdNot yet recruiting
-
Chong Kun Dang PharmaceuticalCompleted
-
AstraZenecaCompletedGastroesophageal Reflux Disease (GERD)United States, France, Poland, Germany
-
Chinese University of Hong KongTerminatedGastrointestinal HemorrhageChina